The IASLC Lung Cancer News (ILCN) is the IASLC's official news medium for thoracic oncology specialists around the globe. ILCN provides its international audience with timely and relevant lung cancer news on topics across specialties and interests, such as novel clinical trial design and statistics, overcoming barriers to NGS testing, tobacco control and smoking/vaping cessation, patient-driven research, patient communication and care delivery during COVID, and more. Only the IASLC—the only international association dedicated to the study of lung cancer—can bring you multidisciplinary nuanced perspectives on daily clinical conundrums and the latest novel research by the true experts in the field.
Featured
ILCN Digital Edition
May 2021 Digital Edition!
What's Inside:
- Approval of Combination Ipilimumab and Nivolumab for Mesothelioma: What Happens Now?
- Biomarkers May Illuminate the Path Forward for PARP Inhibitors in SCLC
- IASLC Survey on Impact of COVID-19 on Trials & Global Regional Mitigation Strategies
- A Patient's Perspective on Skin Toxicity with Afatinib/Cetuximab
- Survivorship in Lung Cancer: An Interview with Dr. Anne Katz
- Advancing Combined Modality Therapy for Early-Stage, Screen-Detected Disease:Adjuvant/Neoadjuvant Therapy
- Deeper Dive: Differences in Smoking and Lung Cancer Incidence Amoing Black and White Young Adults in the United States
CT Screening Symposium News
Understanding Treatment Options and Resistance in EGFR-positive NSCLC
Unfortunately, the inevitability of therapeutic resistance is always looming for patients with EGFR-mutated lung cancer, regardless of PD-1/PD-L1 status. Dr. Karen Reckamp—together with Drs. Ibiaya Dagogo-Jack, Ticiana Leal, and Daniel Tan, as well as patient advocate Sarah Christ—talks through a patient case, exploring all facets of the care continuum for this population. Beginning with discussion of biomarker testing and next-generation sequencing and moving through various opinions on use of whole-brain radiation therapy, combination chemotherapy, first-/second-generation TKIs, and/or osimertinib (depending on region) to other still unidentified mechanisms of resistance to EGFR TKI treatment and ongoing trials looking at novel therapeutic strategies. The ultimate goals of prolonging progression-free survival in the frontline setting and having patients living longer and better lives are reinforced in this forum. Although the patient on the case went on to the ORCHARD trial, each expert weighs in with their individual considerations for potential care paths, based on region and on emerging data.
Global Initiatives
Systemic, Targeted, & Immune Therapies
Industry News & Regulatory Approvals
Supportive & Palliative Care
Names and News
Podcasts
Meeting News
The IASLC World Conference on Lung Cancer 2020 took place on January 28-31, 2021. ILCN brings together the highlights of the meeting, including special discussions by experts and advocates in the field of lung cancer. These exclusive recordings are available for viewing in the WCLC 2020 News Theater. Browse the landing page or download the special ILCN WCLC 2020 PDF Edition available in English, Spanish, Japanese, and Mandarin translations for meeting highlights and more.
Press Releases
The IASLC and ILCN would like to thank AstraZeneca and Daiichi Sankyo for their support.